share_log

Novavax | 4: Statement of changes in beneficial ownership of securities-Officer Dubovsky Filip

Novavax | 4: Statement of changes in beneficial ownership of securities

诺瓦瓦克斯医药 | 4：持股变动声明
SEC announcement ·  03/12 20:49
Moomoo AI 已提取核心信息
On March 10, 2024, Novavax's President of R&D, Filip Dubovsky, completed a stock transaction involving the company's common stock. Dubovsky sold 2,597 shares at a price of $5.45 per share, resulting in a total transaction value of $14,153.65. This sale was part of a transaction coded as 'F', typically indicating a payment of exercise price or tax liability by delivering or withholding securities. On the same day, Dubovsky also acquired 5,376 shares through an exercise or conversion of derivative security, coded as 'M'. Following these transactions, Dubovsky's direct holdings in Novavax amounted to 66,613 shares of common stock.
On March 10, 2024, Novavax's President of R&D, Filip Dubovsky, completed a stock transaction involving the company's common stock. Dubovsky sold 2,597 shares at a price of $5.45 per share, resulting in a total transaction value of $14,153.65. This sale was part of a transaction coded as 'F', typically indicating a payment of exercise price or tax liability by delivering or withholding securities. On the same day, Dubovsky also acquired 5,376 shares through an exercise or conversion of derivative security, coded as 'M'. Following these transactions, Dubovsky's direct holdings in Novavax amounted to 66,613 shares of common stock.
2024年3月10日，Novavax的研发总裁菲利普·杜波夫斯基完成了一项涉及公司普通股的股票交易。杜波夫斯基以每股5.45美元的价格出售了2597股股票，总交易价值为14,153.65美元。此次出售是编码为 “F” 的交易的一部分，通常表示通过交付或预扣证券来支付行使价或纳税义务。同一天，杜波夫斯基还通过行使或转换衍生证券（代号为 “M”）收购了5,376股股票。这些交易之后，杜波夫斯基在Novavax的直接持有量为66,613股普通股。
2024年3月10日，Novavax的研发总裁菲利普·杜波夫斯基完成了一项涉及公司普通股的股票交易。杜波夫斯基以每股5.45美元的价格出售了2597股股票，总交易价值为14,153.65美元。此次出售是编码为 “F” 的交易的一部分，通常表示通过交付或预扣证券来支付行使价或纳税义务。同一天，杜波夫斯基还通过行使或转换衍生证券（代号为 “M”）收购了5,376股股票。这些交易之后，杜波夫斯基在Novavax的直接持有量为66,613股普通股。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息